Covered recipient · General Payments record
MEHRDAD KEVIN ARIANI
Allopathic & Osteopathic Physicians Internal Medicine Interventional Cardiology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$3,865.35
128 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $3,733.08 | 126 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $100.00 | 1 |
| Education | $32.27 | 1 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Medtronic, Inc. | $902.55 | 30 |
| AstraZeneca Pharmaceuticals LP | $399.45 | 11 |
| Abbott Laboratories | $343.53 | 7 |
| Boston Scientific Corporation | $338.00 | 9 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $268.92 | 7 |
| Novartis Pharmaceuticals Corporation | $251.38 | 12 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $151.33 | 12 |
| ABIOMED | $149.93 | 1 |
| Merck Sharp & Dohme LLC | $145.58 | 5 |
| Kiniksa Pharmaceuticals International, plc | $119.87 | 4 |
| Novo Nordisk Inc | $98.63 | 4 |
| Amgen Inc. | $88.27 | 3 |
| ASAHI INTECC USA, INC. | $86.41 | 1 |
| Lexicon Pharmaceuticals, Inc. | $77.34 | 3 |
| E.R. Squibb & Sons, L.L.C. | $70.29 | 3 |
| PFIZER INC. | $69.14 | 3 |
| Gilead Sciences, Inc. | $52.51 | 2 |
| Bayer Healthcare Pharmaceuticals Inc. | $43.85 | 2 |
| Alnylam Pharmaceuticals Inc. | $38.95 | 2 |
| SANOFI-AVENTIS U.S. LLC | $32.36 | 1 |
| Philips North America LLC | $27.14 | 1 |
| Esperion Therapeutics, Inc. | $26.27 | 1 |
| Janssen Pharmaceuticals, Inc | $24.45 | 1 |
| HEARTFLOW, INC. | $22.80 | 1 |
| Edwards Lifesciences Corporation | $19.75 | 1 |
| W. L. Gore & Associates, Inc. | $16.65 | 1 |
Page 3 of 3; records 101–128 of 128 matching records. This page contains 28 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MEHRDAD KEVIN ARIANI
NPI 1942496211 · CMS profile ID 87900
Allopathic & Osteopathic Physicians / Internal Medicine / Interventional Cardiology
NORTHRIDGE, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–128 of 128 matching records. This page contains 28 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1942496211?year=2024&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MEHRDAD KEVIN ARIANI, NPI 1942496211, CMS profile ID 87900. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–128 of 128 matching records. This page contains 28 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1942496211?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). MEHRDAD KEVIN ARIANI, NPI 1942496211, CMS profile ID 87900. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–128 of 128 matching records. This page contains 28 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1942496211?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- MEHRDAD KEVIN ARIANI, NPI 1942496211, CMS profile ID 87900, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–128 of 128 matching records. This page contains 28 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1942496211?year=2024&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
128 matching records · $3,865.35 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–128 of 128.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Medtronic, Inc. | $36.43 | 03/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1119559502 | CMS |
| Medtronic, Inc. | $34.80 | 03/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1119559500 | CMS |
| Medtronic, Inc. | $159.76 | 03/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1119559490 | CMS |
| Kiniksa Pharmaceuticals International, plc | $21.92 | 03/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1154890663 | CMS |
| Medtronic, Inc. | $9.21 | 03/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1119559498 | CMS |
| Novartis Pharmaceuticals Corporation | $20.96 | 03/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086616585 | CMS |
| Medtronic, Inc. | $13.17 | 02/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1119559492 | CMS |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $30.91 | 02/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1080660893 | CMS |
| Merck Sharp & Dohme LLC | $27.26 | 02/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141704652 | CMS |
| PFIZER INC. | $24.00 | 02/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131019030 | CMS |
| Kiniksa Pharmaceuticals International, plc | $28.18 | 02/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1154890649 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $26.82 | 02/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086173974 | CMS |
| Novartis Pharmaceuticals Corporation | $16.67 | 02/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086616591 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $16.56 | 02/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118244953 | CMS |
| Medtronic, Inc. | $10.06 | 02/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1119559494 | CMS |
| Novo Nordisk Inc | $32.27 | 02/08/2024 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1096758636 | CMS |
| Novo Nordisk Inc | $24.86 | 02/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1097456730 | CMS |
| Amgen Inc. | $27.33 | 02/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1115428497 | CMS |
| Boston Scientific Corporation | $20.44 | 02/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1092704824 | CMS |
| AstraZeneca Pharmaceuticals LP | $13.68 | 02/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105733989 | CMS |
| Medtronic, Inc. | $33.93 | 01/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1119559488 | CMS |
| Philips North America LLC | $27.14 | 01/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1146906302 | CMS |
| Novartis Pharmaceuticals Corporation | $26.07 | 01/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086616579 | CMS |
| Novartis Pharmaceuticals Corporation | $28.42 | 01/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086616581 | CMS |
| AstraZeneca Pharmaceuticals LP | $18.98 | 01/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105744266 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $28.87 | 01/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118244957 | CMS |
| Alnylam Pharmaceuticals Inc. | $18.53 | 01/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1125825501 | CMS |
| Edwards Lifesciences Corporation | $19.75 | 01/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1138894595 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,801,699.26 | 89 |
| PY2024 | Recipient | $61,134.47 | 7 |
| PY2024 | Principal investigator | $784,679.33 | 34 |
| PY2023 | Recipient | $50.00 | 1 |
| PY2023 | Principal investigator | $658,346.59 | 98 |
| PY2022 | Recipient | $50.00 | 1 |
| PY2022 | Principal investigator | $539,235.86 | 83 |
| PY2021 | Recipient | $9,400.00 | 1 |
| PY2021 | Principal investigator | $265,601.96 | 187 |
| PY2020 | Principal investigator | $397,144.96 | 150 |
| PY2019 | Principal investigator | $452,933.67 | 150 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
89 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $9,108.34 | 12/31/2025 | Non-covered Recipient Entity Valley Clinical Trials Inc | A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat,MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction | No dispute reported | 06/30/2026 | 1232920033 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $90.00 | 12/30/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS LLC DBA FLOURISH RESEARCH | IS354CS9 | No dispute reported | 06/30/2026 | 1246792215 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $500.00 | 12/17/2025 | Non-covered Recipient Entity Valley Clinical Trials | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220715311 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,575.00 | 12/17/2025 | Non-covered Recipient Entity Valley Clinical Trials | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220715313 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,016.00 | 12/17/2025 | Non-covered Recipient Entity Valley Clinical Trials | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220715315 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,470.00 | 12/12/2025 | Non-covered Recipient Entity Valley Clinical Trials | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220715317 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $171.00 | 12/12/2025 | Non-covered Recipient Entity Valley Clinical Trials | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220715319 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $1,870.00 | 12/10/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS LLC DBA FLOURISH RESEARCH | IS354CS9 | No dispute reported | 06/30/2026 | 1246791447 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,828.00 | 11/19/2025 | Non-covered Recipient Entity Valley Clinical Trials | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220715297 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,828.00 | 11/19/2025 | Non-covered Recipient Entity Valley Clinical Trials | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220715299 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,475.00 | 11/19/2025 | Non-covered Recipient Entity Valley Clinical Trials | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220715301 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,623.00 | 11/19/2025 | Non-covered Recipient Entity Valley Clinical Trials | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220715303 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,470.00 | 11/19/2025 | Non-covered Recipient Entity Valley Clinical Trials | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220715305 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $171.00 | 11/19/2025 | Non-covered Recipient Entity Valley Clinical Trials | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220715307 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,623.00 | 11/19/2025 | Non-covered Recipient Entity Valley Clinical Trials | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220715309 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.96 | 11/19/2025 | Non-covered Recipient Entity Valley Clinical Trials | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220715321 |
| Principal investigator 1 | Impulse Dynamics (USA) Inc. | $630.00 | 11/13/2025 | Non-covered Recipient Entity Valley Clinical Trials | Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy | No dispute reported | 06/30/2026 | 1214123218 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $5,007.72 | 11/11/2025 | Non-covered Recipient Entity Valley Clinical Trials | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220996968 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $900.00 | 11/10/2025 | Non-covered Recipient Entity Valley Clinical Trials | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220715295 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $1,669.24 | 10/22/2025 | Non-covered Recipient Entity Valley Clinical Trials | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220996966 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,475.00 | 10/20/2025 | Non-covered Recipient Entity Valley Clinical Trials | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220715287 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $575.00 | 10/14/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS LLC DBA FLOURISH RESEARCH | IS354CS9 | No dispute reported | 06/30/2026 | 1246789268 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $1,000.00 | 10/14/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS LLC DBA FLOURISH RESEARCH | IS354CS9 | No dispute reported | 06/30/2026 | 1246789272 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $5,000.00 | 10/14/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS LLC DBA FLOURISH RESEARCH | IS354CS9 | No dispute reported | 06/30/2026 | 1246789275 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $5,200.00 | 10/14/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS LLC DBA FLOURISH RESEARCH | IS354CS9 | No dispute reported | 06/30/2026 | 1246789279 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $24,842.70 | 10/14/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS LLC DBA FLOURISH RESEARCH | IS354CS9 | No dispute reported | 06/30/2026 | 1246789283 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $500.00 | 10/02/2025 | Non-covered Recipient Entity Valley Clinical Trials | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220715253 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,618.00 | 10/02/2025 | Non-covered Recipient Entity Valley Clinical Trials | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220715255 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,500.00 | 10/02/2025 | Non-covered Recipient Entity Valley Clinical Trials | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220715257 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,500.00 | 10/02/2025 | Non-covered Recipient Entity Valley Clinical Trials | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220715259 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $14,000.00 | 10/02/2025 | Non-covered Recipient Entity Valley Clinical Trials | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220715261 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,000.00 | 10/02/2025 | Non-covered Recipient Entity Valley Clinical Trials | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220715263 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,250.00 | 10/02/2025 | Non-covered Recipient Entity Valley Clinical Trials | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220715265 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,400.00 | 10/02/2025 | Non-covered Recipient Entity Valley Clinical Trials | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220715267 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,828.00 | 10/02/2025 | Non-covered Recipient Entity Valley Clinical Trials | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220715269 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,828.00 | 10/02/2025 | Non-covered Recipient Entity Valley Clinical Trials | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220715271 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,828.00 | 10/02/2025 | Non-covered Recipient Entity Valley Clinical Trials | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220715273 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,623.00 | 10/02/2025 | Non-covered Recipient Entity Valley Clinical Trials | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220715275 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,470.00 | 10/02/2025 | Non-covered Recipient Entity Valley Clinical Trials | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220715277 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $171.00 | 10/02/2025 | Non-covered Recipient Entity Valley Clinical Trials | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220715279 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,623.00 | 10/02/2025 | Non-covered Recipient Entity Valley Clinical Trials | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220715281 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,470.00 | 10/02/2025 | Non-covered Recipient Entity Valley Clinical Trials | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220715283 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $171.00 | 10/02/2025 | Non-covered Recipient Entity Valley Clinical Trials | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220715285 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,000.00 | 10/02/2025 | Non-covered Recipient Entity Valley Clinical Trials | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220715289 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,000.00 | 10/02/2025 | Non-covered Recipient Entity Valley Clinical Trials | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220715291 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,250.00 | 10/02/2025 | Non-covered Recipient Entity Valley Clinical Trials | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220715293 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $3,338.48 | 09/30/2025 | Non-covered Recipient Entity Valley Clinical Trials | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220996964 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $41,443.48 | 09/30/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS | Evaluation of Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention (V-INTERVENTION) | No dispute reported | 06/30/2026 | 1190313599 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $219.78 | 09/24/2025 | Non-covered Recipient Entity Valley Clinical Trials | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220715251 |
| Principal investigator 1 | Amgen Inc. | $81,885.60 | 09/23/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS, INC. | A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a) | No dispute reported | 06/30/2026 | 1246651130 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $20,500.00 | 09/18/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS LLC | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With Established Cardiovascular Disease | No dispute reported | 06/30/2026 | 1190309570 |
| Principal investigator 1 | Impulse Dynamics (USA) Inc. | $910.00 | 09/15/2025 | Non-covered Recipient Entity Valley Clinical Trials | Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy | No dispute reported | 06/30/2026 | 1214123202 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $2,708.25 | 09/11/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS | A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on the progression of calcific aortic valve stenosis [Lp(a)FRONTIERS CAVS] | No dispute reported | 06/30/2026 | 1190298573 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $450.00 | 09/09/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS LLC DBA FLOURISH RESEARCH | IS354CS9 | No dispute reported | 06/30/2026 | 1246787273 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $23,450.20 | 09/08/2025 | Non-covered Recipient Entity Valley Clinical Trials Inc | A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat,MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction | No dispute reported | 06/30/2026 | 1232920031 |
| Principal investigator 1 | Organon Llc | $2,500.00 | 09/08/2025 | Non-covered Recipient Entity Valley Clinical Trials Inc | 1242-035 | No dispute reported | 06/30/2026 | 1173042168 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $99.90 | 08/26/2025 | Non-covered Recipient Entity Valley Clinical Trials | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220715249 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $14,159.22 | 08/19/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) | No dispute reported | 06/30/2026 | 1190298570 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $11,628.38 | 08/19/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease | No dispute reported | 06/30/2026 | 1190298578 |
| Principal investigator 1 | Impulse Dynamics (USA) Inc. | $700.00 | 08/14/2025 | Non-covered Recipient Entity Valley Clinical Trials | Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy | No dispute reported | 06/30/2026 | 1214123200 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $5,007.72 | 08/12/2025 | Non-covered Recipient Entity Valley Clinical Trials | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220996962 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $54.00 | 07/30/2025 | Non-covered Recipient Entity Valley Clinical Trials | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220715245 |
| Principal investigator 1 | Amgen Inc. | $3,487.19 | 07/28/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS | A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a) | No dispute reported | 06/30/2026 | 1246651158 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $59.94 | 07/28/2025 | Non-covered Recipient Entity Valley Clinical Trials | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220715247 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $1,669.24 | 07/18/2025 | Non-covered Recipient Entity Valley Clinical Trials | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220996960 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $460.00 | 07/02/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS LLC DBA FLOURISH RESEARCH | IS354CS9 | No dispute reported | 06/30/2026 | 1246784996 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $600.00 | 07/02/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS LLC DBA FLOURISH RESEARCH | IS354CS9 | No dispute reported | 06/30/2026 | 1246785001 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $650.00 | 07/02/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS LLC DBA FLOURISH RESEARCH | IS354CS9 | No dispute reported | 06/30/2026 | 1246785005 |
| Principal investigator 1 | Amgen Inc. | $103,053.28 | 06/26/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS, INC. | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF) | No dispute reported | 06/30/2026 | 1246651134 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $34.98 | 06/24/2025 | Non-covered Recipient Entity Valley Clinical Trials | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220715239 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $359.64 | 06/24/2025 | Non-covered Recipient Entity Valley Clinical Trials | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220715241 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $36.50 | 06/24/2025 | Non-covered Recipient Entity Valley Clinical Trials | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220715243 |
| Principal investigator 1 | Amgen Inc. | $13,825.66 | 06/20/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF) | No dispute reported | 06/30/2026 | 1246651161 |
| Principal investigator 1 | Impulse Dynamics (USA) Inc. | $35.00 | 06/12/2025 | Non-covered Recipient Entity Valley Clinical Trials | Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy | No dispute reported | 06/30/2026 | 1214123204 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $3,338.00 | 06/11/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS | A Phase II, Randomized, Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure in Participants with Atherosclerotic Cardiovascular Disease or Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol | No dispute reported | 06/30/2026 | 1185551295 |
| Principal investigator 1 | Impulse Dynamics (USA) Inc. | $735.00 | 05/14/2025 | Non-covered Recipient Entity Valley Clinical Trials | Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy | No dispute reported | 06/30/2026 | 1214123216 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $92,561.85 | 04/07/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS | HPS-4/TIMI 65/ORION-4: A Double-blind Randomized Placebo-controlled Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Atherosclerotic Cardiovascular Disease | No dispute reported | 06/30/2026 | 1190313593 |
| Principal investigator 1 | Impulse Dynamics (USA) Inc. | $630.00 | 03/26/2025 | Non-covered Recipient Entity Valley Clinical Trials | Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy | No dispute reported | 06/30/2026 | 1214123214 |
| Principal investigator 1 | Impulse Dynamics (USA) Inc. | $250.00 | 03/13/2025 | Non-covered Recipient Entity Valley Clinical Trials | Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy | No dispute reported | 06/30/2026 | 1214123206 |
| Principal investigator 1 | Impulse Dynamics (USA) Inc. | $250.00 | 03/13/2025 | Non-covered Recipient Entity Valley Clinical Trials | Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy | No dispute reported | 06/30/2026 | 1214123208 |
| Principal investigator 1 | Impulse Dynamics (USA) Inc. | $300.00 | 03/13/2025 | Non-covered Recipient Entity Valley Clinical Trials | Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer) | No dispute reported | 06/30/2026 | 1214123210 |
| Principal investigator 1 | Impulse Dynamics (USA) Inc. | $405.00 | 02/27/2025 | Non-covered Recipient Entity Valley Clinical Trials | Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer) | No dispute reported | 06/30/2026 | 1214123212 |
| Principal investigator 1 | Eli Lilly and Company | $7,540.56 | 02/25/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | No dispute reported | 06/30/2026 | 1187892774 |
| Principal investigator 1 | AstraZeneca UK Limited | $541,597.30 | 01/29/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS | A Phase IIb Two cohort Randomised Placebo controlled Double blind Multicentre Dose ranging Study of AZD5462 in Stable Patients with Chronic Heart Failure | No dispute reported | 06/30/2026 | 1185551293 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $77,790.26 | 01/27/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) | No dispute reported | 06/30/2026 | 1190313595 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $5,139.76 | 01/15/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease | No dispute reported | 06/30/2026 | 1190313607 |
| Principal investigator 1 | AstraZeneca UK Limited | $181,295.00 | 01/13/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS | A Phase II, Randomized, Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure in Participants with Atherosclerotic Cardiovascular Disease or Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol | No dispute reported | 06/30/2026 | 1185551291 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $23,930.13 | 01/07/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS | A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on the progression of calcific aortic valve stenosis [Lp(a)FRONTIERS CAVS] | No dispute reported | 06/30/2026 | 1190313601 |
| Principal investigator 1 | Eli Lilly and Company | $390,422.00 | 01/06/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | No dispute reported | 06/30/2026 | 1187892602 |